The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE
OMB APPROVAL
OMB Number: 3235-0006
Expires: July 31, 2015
Estimated average burden
hours per response: 23.8
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
AGOMAB THERAPEUTICS NV SPONSORED ADS 00860C102 17,079,592 1,538,702 SH SOLE 1,538,702 0 0
AVALYN PHARMACEUTICALS INC COM SHS 05348Y105 26,490,686 929,824 SH SOLE 929,824 0 0
EVOMMUNE INC COM SHS 30054Y107 804,210 97,362 SH SOLE 97,362 0 0
INVENTIVA SA ADS 46124U107 13,406,438 3,633,181 SH SOLE 3,633,181 0 0
KESTRA MED TECHNOLOGIES LTD SHS G52441105 77,194,329 2,728,679 SH SOLE 2,728,679 0 0
MINERALYS THERAPEUTICS INC COM 603170101 40,004,874 1,591,917 SH SOLE 1,591,917 0 0
NYXOAH S A SHS B6S7WD106 720,439 522,057 SH SOLE 522,057 0 0